1-5 of 5
Bruyère Mahuzier
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Siremadlin, a Human Double Minute-2 (HDM2) Inhibitor, Added to Ruxolitinib after Suboptimal Response to Ruxolitinib Alone in Patients with Myelofibrosis: Results from Part 1 of the Phase 1/2 Adore Study

Florian H Heidel, Andrew Charles Perkins, Andreas Reiter, Carl C. Crodel, Caroline Hasselbalch Riley, María Teresa Gómez-Casares, Istvan Takacs, Heiko Becker, Thomas Lehmann, Olga Vinogradova, Kate Burbury, Alessandro M. Vannucchi, Vikas Gupta, Claire Harrison, Marielle Wondergem, Jean-Jacques Kiladjian, Grace Cleary, Angela Zhang, Bruyère Mahuzier, Jagannath Kota, Anirudh Prahallad, David M Ross
Journal: Blood
Blood (2022) 140 (Supplement 1): 590–593.
https://doi.org/10.1182/blood-2022-158501
Published: 2022
Journal Articles

Safety Analysis of Ruxolitinib (RUX) Vs Best Available Therapy (BAT) in Patients (pts) with Steroid-Refractory (SR) Acute Graft-Vs-Host Disease (aGVHD) in the Randomized Phase 3 REACH2 Study

Nikolas Von Bubnoff, Jason P Butler, MBBS, MMedSc, FRACP, FRCPA, Eva Maria Wagner, MD, Edouard Forcade, MD PhD, Jaime Sanz Caballer, MD PhD, Domenico Russo, MD, Giovanni Grillo, MD, Tsila Zuckerman, MD, Sinem Civriz Bozdag, MD, Francis A. Ayuk, Friedrich Stoelzel, PD, MD, Sung-Soo Yoon, MD PhD, Jose Valentín García Gutiérrez, MD PhD, David Ritchie, MD ChB, PhD FRACP, FRCPA, Claude-Eric Bulabois, MD, Marie Thérèse Rubio, MD PhD, Judith Xu, Juliane Morando, MD, Bruyère Mahuzier, Pharm D, Satish Mahadevaiah Chandraiah, Gérard Socié, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 40–42.
https://doi.org/10.1182/blood-2020-137603
Published: 2020
Journal Articles

Efficacy and safety of ruxolitinib in regularly transfused patients with thalassemia: results from a phase 2a study

Clinical Trials & Observations
Ali T. Taher, Zeynep Karakas, Elena Cassinerio, Noppadol Siritanaratkul, Antonis Kattamis, Aurelio Maggio, Stefano Rivella, Norbert Hollaender, Bruyère Mahuzier, Brian Gadbaw, Yesim Aydinok
Journal: Blood
Blood (2018) 131 (2): 263–265.
https://doi.org/10.1182/blood-2017-06-790121
Published: 2018
Includes: Supplemental data
Journal Articles

Efficacy and Safety of Ruxolitinib in Regularly Transfused Patients with Thalassemia: Results from Single-Arm, Multicenter, Phase 2a Truth Study

Yesim Aydinok, MD, Zeynep Karakas, MD, Elena Cassinerio, MD, Noppadol Siritanaratkul, MD, Antonis Kattamis, MD, Aurelio Maggio, MD, Norbert Hollaender, PhD, Bruyère Mahuzier, Pharm D, Brian Gadbaw, MD, Ali T. Taher, MD PhD
Journal: Blood
Blood (2016) 128 (22): 852.
https://doi.org/10.1182/blood.V128.22.852.852
Published: 2016
Journal Articles

An Open-Label, Multicenter, 2-Arm, Dose-Finding, Phase 1b Study of the Combination of Ruxolitinib and Buparlisib (BKM120) in Patients with Myelofibrosis: Results from HARMONY Study

Simon T Durrant, Arnon Nagler, Alessandro M Vannucchi, David Lavie, MD, Charles Chuah, Francesco Passamonti, Heinz Gisslinger, MD, Philipp le Coutre, Prashanth Gopalakrishna, MBBS, MRCS, Bruyère Mahuzier, Shuyuan Mo, Joaquin Martinez-Lopez
Journal: Blood
Blood (2015) 126 (23): 827.
https://doi.org/10.1182/blood.V126.23.827.827
Published: 2015